Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
Sanofi India, Schaeffler India share prices will remain in focus on Thursday as will declare dividend today. The meeting of ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
3d
GlobalData on MSNSanofi’s Sarclisa combo approved in Japan for newly diagnosed MMSanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
5d
GlobalData on MSNSanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Even as President Donald Trump wages a very public fight against diversity, equity and inclusion (DEI) initiatives in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results